Glembatumumab vedotin
- Generic Name
- Glembatumumab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1182215-65-1
- Unique Ingredient Identifier
- 1568H6A58U
- Background
A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
- Indication
Investigated for use/treatment in melanoma.
- Associated Conditions
- -
- Associated Therapies
- -
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of Virginia
- Registration Number
- NCT03473691
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03326258
Individual Patient Expanded Access-Glembatumumab Vedotin
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Celldex Therapeutics
- Registration Number
- NCT03067935
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT02487979
- Locations
- ๐บ๐ธ
Nationwide Children's Hospital, Columbus, Ohio, United States
๐บ๐ธGolisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
๐บ๐ธKaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT02363283
- Locations
- ๐บ๐ธ
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
๐บ๐ธUniversity of Kansas Clinical Research Center, Fairway, Kansas, United States
๐บ๐ธUT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT02302339
- Locations
- ๐บ๐ธ
Florida Cancer Specialists, West Palm Beach, Florida, United States
๐บ๐ธHenry Ford Hospital, Detroit, Michigan, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.